Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 30,000 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Gad also recently made the following trade(s):

• On Friday, September 13th, Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $13.47, for a total value of $875,550.00.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $14.31 on Wednesday. The firm has a 50-day moving average price of $12.70 and a two-hundred day moving average price of $13.52. Y-mAbs Therapeutics, Inc. has a twelve month low of $4.69 and a twelve month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. During the same period last year, the business earned ($0.14) earnings per share. On average, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on YMAB shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets cut their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently made changes to their positions in YMAB. Ameritas Investment Partners Inc. boosted its stake in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Y-mAbs Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after purchasing an additional 3,340 shares during the last quarter. Caxton Associates LP purchased a new position in Y-mAbs Therapeutics in the 1st quarter valued at about $306,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Y-mAbs Therapeutics during the second quarter worth about $297,000. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.